BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 24811995)

  • 1. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD.
    De Preter V; Machiels K; Joossens M; Arijs I; Matthys C; Vermeire S; Rutgeerts P; Verbeke K
    Gut; 2015 Mar; 64(3):447-58. PubMed ID: 24811995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases.
    Farkas K; Saródi Z; Bálint A; Földesi I; Tiszlavicz L; Szűcs M; Nyári T; Tajti J; Nagy F; Szepes Z; Bor R; Annaházi A; Róka R; Molnár T
    J Crohns Colitis; 2015 Mar; 9(3):231-7. PubMed ID: 25585596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pouch Inflammation Is Associated With a Decrease in Specific Bacterial Taxa.
    Reshef L; Kovacs A; Ofer A; Yahav L; Maharshak N; Keren N; Konikoff FM; Tulchinsky H; Gophna U; Dotan I
    Gastroenterology; 2015 Sep; 149(3):718-27. PubMed ID: 26026389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease.
    Ahmed I; Greenwood R; Costello B; Ratcliffe N; Probert CS
    Aliment Pharmacol Ther; 2016 Mar; 43(5):596-611. PubMed ID: 26806034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal volatile organic compounds analysis using field asymmetric ion mobility spectrometry: non-invasive diagnostics in paediatric inflammatory bowel disease.
    van Gaal N; Lakenman R; Covington J; Savage R; de Groot E; Bomers M; Benninga M; Mulder C; de Boer N; de Meij T
    J Breath Res; 2017 Nov; 12(1):016006. PubMed ID: 28439048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.
    Machiels K; Joossens M; Sabino J; De Preter V; Arijs I; Eeckhaut V; Ballet V; Claes K; Van Immerseel F; Verbeke K; Ferrante M; Verhaegen J; Rutgeerts P; Vermeire S
    Gut; 2014 Aug; 63(8):1275-83. PubMed ID: 24021287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The faecal scent of inflammatory bowel disease: Detection and monitoring based on volatile organic compound analysis.
    Bosch S; Wintjens DSJ; Wicaksono A; Kuijvenhoven J; van der Hulst R; Stokkers P; Daulton E; Pierik MJ; Covington JA; de Meij TGJ; de Boer NKH
    Dig Liver Dis; 2020 Jul; 52(7):745-752. PubMed ID: 32402741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch.
    Werner L; Sturm A; Roggenbuck D; Yahav L; Zion T; Meirowithz E; Ofer A; Guzner-Gur H; Tulchinsky H; Dotan I
    J Crohns Colitis; 2013 Dec; 7(11):e522-32. PubMed ID: 23639628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic Analysis Identifies Three Reliable Biomarkers of Intestinal Inflammation in the Stools of Patients With Inflammatory Bowel Disease.
    Vitali R; Palone F; Armuzzi A; Fulci V; Negroni A; Carissimi C; Cucchiara S; Stronati L
    J Crohns Colitis; 2023 Jan; 17(1):92-102. PubMed ID: 36040453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fecal neutrophil gelatinase-associated lipocalin is a surrogate marker of inflammation in inflammatory bowel disease].
    Zinkevich OD; Mukhametova DD; Abdulganieva DI; Safina NA; Koporulina MO; Odintsova AKh
    Eksp Klin Gastroenterol; 2014; (10):22-7. PubMed ID: 25911926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive exhaled volatile organic biomarker analysis to detect inflammatory bowel disease (IBD).
    Arasaradnam RP; McFarlane M; Daulton E; Skinner J; O'Connell N; Wurie S; Chambers S; Nwokolo C; Bardhan K; Savage R; Covington J
    Dig Liver Dis; 2016 Feb; 48(2):148-53. PubMed ID: 26682719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease.
    Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Voudouri T; Kouroumalis EA
    Inflamm Bowel Dis; 2006 Feb; 12(2):100-5. PubMed ID: 16432373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and Clinical Significance of Elafin in Inflammatory Bowel Disease.
    Zhang W; Teng G; Wu T; Tian Y; Wang H
    Inflamm Bowel Dis; 2017 Dec; 23(12):2134-2141. PubMed ID: 29084078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of inflammatory bowel disease with urinary metabolic profiling.
    Williams HR; Cox IJ; Walker DG; North BV; Patel VM; Marshall SE; Jewell DP; Ghosh S; Thomas HJ; Teare JP; Jakobovits S; Zeki S; Welsh KI; Taylor-Robinson SD; Orchard TR
    Am J Gastroenterol; 2009 Jun; 104(6):1435-44. PubMed ID: 19491857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faecal Volatile Organic Compound Analysis in De Novo Paediatric Inflammatory Bowel Disease by Gas Chromatography-Ion Mobility Spectrometry: A Case-Control Study.
    Vermeer E; Jagt JZ; Stewart TK; Covington JA; Struys EA; de Jonge R; de Boer NKH; de Meij TGJ
    Sensors (Basel); 2024 Apr; 24(9):. PubMed ID: 38732837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between fecal lactoferrin and inflammatory bowel disease.
    Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ
    Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy.
    Stephens NS; Siffledeen J; Su X; Murdoch TB; Fedorak RN; Slupsky CM
    J Crohns Colitis; 2013 Mar; 7(2):e42-8. PubMed ID: 22626506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease.
    Zhang P; Liu X; Guo A; Xiong J; Fu Y; Zou K
    Dig Dis Sci; 2016 Sep; 61(9):2608-18. PubMed ID: 27056038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease.
    Aomatsu T; Imaeda H; Matsumoto K; Kimura E; Yoden A; Tamai H; Fujiyama Y; Mizoguchi E; Andoh A
    Aliment Pharmacol Ther; 2011 Oct; 34(8):941-8. PubMed ID: 21848856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis.
    Nielsen OH; Gionchetti P; Ainsworth M; Vainer B; Campieri M; Borregaard N; Kjeldsen L
    Am J Gastroenterol; 1999 Oct; 94(10):2923-8. PubMed ID: 10520846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.